OcuMension Therapeutics announced an agreement with Alcon Inc. where OcuMension will acquire commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops. Financial terms were not disclosed. Shanghai-based OcuMension was advised by Morrison & Foerster. Alcon was represented by a Gibson, Dunn & Crutcher team led by partners Branden Berns, Karen Spindler and Alison Beal.
Health Care
August 15, 2024, 3:25 PM